DONGSUNG PHARMACEUTICAL CO.,LTD (동성제약(주))
KOSPI Stock Code: 002210 | DART Corp Code: 00116268
English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
| English name (as registered with DART) | DONGSUNG PHARMACEUTICAL CO.,LTD |
|---|---|
| Korean legal name | 동성제약(주) |
| Alternate names | 동성제약 |
| Market | KOSPI |
| Stock Code | 002210 |
| DART Corp Code | 00116268 |
| CEO | 최용석 |
| Business Registration No. | 2118125288 |
| Corporate Registration No. | 1101110008200 |
| Established Date | 1957-11-25 |
| Fiscal Month | 12 |
| KSIC Industry Code | 212 |
| Address (KO) | 서울특별시 도봉구 도봉로 683 (방학동) 동성빌딩 |
| Homepage | https://dongsung-pharm.co.kr/ |
| source_url | https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260506000554 |
| verified_at | 2026-11-01T02:16:01.415Z |
Annual Financial Summary (KRW)
Fiscal Year: 2025 | Basis: OFS (Separate) | Currency: KRW | Filing Source: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260506000554
| Account | FY2025 (Current) | FY2024 (Prior) |
|---|---|---|
| Revenue (매출액) | KRW 87,168,895,112 | KRW 88,448,234,133 |
| Operating Income (영업이익) | KRW -10,118,316,902 | KRW -5,731,935,846 |
| Net Income (당기순이익) | KRW -25,737,002,341 | KRW -14,571,588,545 |
| Total Assets (자산총계) | KRW 168,443,037,239 | KRW 140,668,093,773 |
| Total Liabilities (부채총계) | KRW 145,072,185,596 | KRW 96,700,571,202 |
| Total Equity (자본총계) | KRW 23,370,851,643 | KRW 43,967,522,571 |
Recent DART Filings (Last 90 Days, up to 20)
| Filed Date | Receipt No. | English Title | Korean Title | Filer |
|---|---|---|---|---|
2026-09-30 | 20260930801211 | Court Ruling or Decision on Lawsuit, etc. | 소송등의판결ㆍ결정 | 동성제약 |
2026-09-14 | 20260914800573 | Court Ruling or Decision on Lawsuit, etc. | 소송등의판결ㆍ결정 | 동성제약 |
2026-08-27 | 20260827001015 | Disclosure of Current Status of Large-scale Business Groups [Quarterly Disclosure (For individual company)] | 대규모기업집단현황공시[분기별공시(개별회사용)] | 동성제약 |
2026-08-18 | 20260818000136 | [Corrected description]Semi-annual Report (2026.06) | [기재정정]반기보고서 (2026.06) | 동성제약 |
2026-08-14 | 20260814004042 | Semi-annual Report (2026.06) | 반기보고서 (2026.06) | 동성제약 |
2026-08-14 | 20260814001107 | Matters concerning payment amount for each payment method-payment period and Dispute Resolution Organization | 지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항 | 동성제약 |
Source & Disclaimer
source_url: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260506000554 | verified_at: 2026-11-01T02:16:01.415Z
Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.